0 9 Histamine Histamine NNP 10 19 modulates modulate VBZ 20 23 the the DT 24 34 expression expression NN 35 37 of of IN 38 43 c-fos c-fos NN 44 51 through through IN 52 58 cyclic cyclic JJ 59 62 AMP AMP NNP 63 73 production production NN 74 77 via via IN 78 81 the the DT 82 84 H2 h2 NN 85 93 receptor receptor NN 94 96 in in IN 97 100 the the DT 101 106 human human JJ 107 119 promonocytic promonocytic JJ 120 124 cell cell NN 125 129 line line NN 130 134 U937 u937 NN 134 135 . . . 137 139 We we PRP 140 148 examined examine VBD 149 152 the the DT 153 160 effects effect NNS 161 163 of of IN 164 173 histamine histamine NN 174 177 and and CC 178 181 its its PRP$ 182 190 agonists agonist NNS 191 193 on on IN 194 197 the the DT 198 208 expression expression NN 209 211 of of IN 212 215 the the DT 216 221 c-fos c-fos NN 222 225 and and CC 226 231 c-myc c-myc NN 232 247 proto-oncogenes proto-oncogene NNS 248 250 at at IN 251 254 the the DT 255 270 transcriptional transcriptional JJ 271 274 and and CC 275 288 translational translational JJ 289 295 levels level NNS 296 298 in in IN 299 302 the the DT 303 308 human human JJ 309 321 promonocytic promonocytic JJ 322 326 U937 u937 NN 327 331 cell cell NN 332 336 line line NN 336 337 . . . 338 347 Histamine Histamine NNP 348 359 transiently transiently RB 360 369 increased increase VBD 370 374 cAMP camp NN 375 378 and and CC 379 384 c-fos c-fos NN 385 395 expression expression NN 396 403 through through IN 404 406 H2 h2 NN 407 416 receptors receptor NNS 416 417 . . . 418 427 Dibutyryl Dibutyryl NNP 428 432 cAMP cAMP NNP 433 437 also also RB 438 447 increased increase VBD 448 453 c-fos c-fos NN 454 458 mRNA mrna NN 459 462 and and CC 463 470 protein protein NN 470 471 , , , 472 475 and and CC 476 482 levels level NNS 483 491 remained remain VBD 492 500 elevated elevate VBN 501 505 even even RB 506 511 after after IN 512 514 12 12 CD 515 517 hr hr NN 518 520 of of IN 521 530 treatment treatment NN 530 531 . . . 532 547 Dose-dependence dose-dependence NN 548 555 studies study NNS 556 561 using use VBG 562 571 histamine histamine NN 572 575 and and CC 576 584 dimaprit dimaprit NN 585 591 showed show VBD 592 596 that that IN 597 600 the the DT 601 605 EC50 ec50 NN 606 612 values value NNS 613 616 for for IN 617 621 cAMP camp NN 622 632 production production NN 633 636 and and CC 637 642 c-fos c-fos NN 643 651 increase increase NN 652 656 were be VBD 657 664 similar similar JJ 664 665 , , , 666 676 suggesting suggest VBG 677 681 that that IN 682 686 cAMP camp NN 687 692 might might MD 693 695 be be VB 696 704 involved involve VBN 705 707 in in IN 708 713 c-fos c-fos NN 714 723 induction induction NN 724 727 via via IN 728 730 H2 h2 NN 731 740 receptors receptor NNS 740 741 . . . 742 753 Furthermore furthermore RB 753 754 , , , 755 762 studies study NNS 763 770 carried carry VBD 771 774 out out RP 775 780 using use VBG 781 783 H7 h7 NN 783 784 , , , 785 786 a a DT 787 794 protein protein NN 795 801 kinase kinase NNP 802 811 A/protein A/protein NNP 812 818 kinase kinase NNP 819 820 C C NNP 821 830 inhibitor inhibitor NN 830 831 , , , 832 839 blocked block VBD 840 845 c-fos c-fos NN 846 855 induction induction NN 855 856 , , , 857 864 whereas whereas IN 865 867 no no DT 868 874 effect effect NN 875 878 was be VBD 879 887 observed observe VBN 888 892 with with IN 893 912 bisindolylmaleimide bisindolylmaleimide NN 912 913 , , , 914 915 a a DT 916 924 specific specific JJ 925 932 protein protein NN 933 939 kinase kinase NNP 940 941 C C NNP 942 951 inhibitor inhibitor NN 951 952 . . . 953 955 No no DT 956 968 modification modification NN 969 971 of of IN 972 977 c-myc c-myc NN 978 988 expression expression NN 989 994 could could MD 995 997 be be VB 998 1006 detected detect VBN 1007 1009 on on IN 1010 1019 treatment treatment NN 1020 1024 with with IN 1025 1034 histamine histamine NN 1035 1037 or or CC 1038 1041 its its PRP$ 1042 1051 analogues analogue NNS 1051 1052 . . . 1053 1065 Nevertheless nevertheless RB 1065 1066 , , , 1067 1076 dibutyryl dibutyryl NN 1077 1081 cAMP camp NN 1082 1089 induced induce VBD 1090 1091 a a DT 1092 1107 down-regulation down-regulation NN 1108 1110 of of IN 1111 1114 the the DT 1115 1121 levels level NNS 1122 1124 of of IN 1125 1129 this this DT 1130 1144 proto-oncogene proto-oncogene NN 1144 1145 . . . 1146 1148 In in IN 1149 1157 addition addition NN 1157 1158 , , , 1159 1168 dibutyryl dibutyryl NN 1169 1173 cAMP camp NN 1174 1183 inhibited inhibit VBD 1184 1188 cell cell NN 1189 1195 growth growth NN 1196 1198 in in IN 1199 1200 a a DT 1201 1215 dose-dependent dose-dependent JJ 1216 1222 manner manner NN 1222 1223 , , , 1224 1231 whereas whereas IN 1232 1241 histamine histamine NN 1242 1248 failed fail VBD 1249 1251 to to TO 1252 1258 affect affect VB 1259 1272 proliferation proliferation NN 1273 1276 and and CC 1277 1292 differentiation differentiation NN 1293 1295 of of IN 1296 1300 U937 u937 NN 1301 1306 cells cell NNS 1306 1307 . . . 1308 1313 Cells cell NNS 1314 1324 pretreated pretreate VBN 1325 1329 with with IN 1330 1338 dimaprit dimaprit NN 1339 1345 showed show VBD 1346 1347 a a DT 1348 1356 decrease decrease NN 1357 1359 in in IN 1360 1363 the the DT 1364 1368 cAMP camp NN 1369 1377 response response NN 1378 1380 to to TO 1381 1391 subsequent subsequent JJ 1392 1400 addition addition NN 1401 1403 of of IN 1404 1406 H2 h2 NN 1407 1415 agonists agonist NNS 1415 1416 , , , 1417 1424 whereas whereas IN 1425 1428 the the DT 1429 1433 cAMP camp NN 1434 1442 response response NN 1443 1445 to to TO 1446 1459 prostaglandin prostaglandin NN 1460 1462 E2 e2 NN 1463 1471 remained remain VBD 1472 1481 unaltered unaltered JJ 1481 1482 . . . 1483 1487 This this DT 1488 1498 homologous homologous JJ 1499 1508 mechanism mechanism NN 1509 1511 of of IN 1512 1514 H2 h2 NN 1515 1523 receptor receptor NN 1524 1539 desensitization desensitization NN 1540 1543 was be VBD 1544 1548 time time NN 1549 1558 dependent dependent JJ 1558 1559 . . . 1560 1565 These these DT 1566 1573 results result NNS 1574 1582 indicate indicate VBP 1583 1587 that that IN 1588 1597 histamine histamine NN 1598 1607 activates activate VBZ 1608 1615 several several JJ 1616 1626 mechanisms mechanism NNS 1627 1635 involved involve VBN 1636 1638 in in IN 1639 1642 the the DT 1643 1652 induction induction NN 1653 1655 of of IN 1656 1671 differentiation differentiation NN 1671 1672 , , , 1673 1677 such such JJ 1678 1680 as as IN 1681 1685 cAMP camp NN 1686 1689 and and CC 1690 1695 c-fos c-fos NN 1696 1706 production production NN 1706 1707 , , , 1708 1711 but but CC 1712 1717 fails fail VBZ 1718 1720 to to TO 1721 1728 promote promote VB 1729 1744 differentiation differentiation NN 1745 1747 of of IN 1748 1752 U937 u937 NN 1753 1758 cells cell NNS 1758 1759 , , , 1760 1770 apparently apparently RB 1771 1774 due due JJ 1775 1777 to to TO 1778 1781 the the DT 1782 1787 rapid rapid JJ 1788 1803 desensitization desensitization NN 1804 1806 of of IN 1807 1809 H2 h2 NN 1810 1819 receptors receptor NNS 1819 1820 . . .